Vaccinia virus (ATCC® VR-1774)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen 1 mL per vial

Permits and Restrictions

View Permits

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain CL
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Product Format frozen 1 mL per vial
Storage Conditions  -70°C or colder
VR-1774 is produced in BSC-40 cells, which is a change in cell line from ATCC VR-117 to increase titer.
Effect on Host
 CPE, refractile cell rounding
CPE, refractile cell rounding
Recommended Host

Production Host:  BSC-40 (ATCC® CRL-2761)

BSC-40 (ATCC CRL-2761)
Growth Conditions
Temperature: 37°C
Growth Conditions: Plate cells 24-48 hours in advance and infect when cultures are 90 to 95% confluent. Remove medium and inoculate with a small volume (e.g. 1 mL per 25 cm2) of virus diluted to provide an optimal MOI (e.g. 0.1). Adsorb 30 minutes at 37°C in a humidified 5% CO2 atmosphere, rocking every 7-10 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
Incubation: 1-3 days
Effect on Host
 CPE, refractile cell rounding
CPE, refractile cell rounding
Name of Depositor F Fenner, Australian National University
Most likely derived from New York City Department of Health strain of vaccinia virus. Cell culture adapted to BSC-40 cells.

Fenner, F and Burnet, FM. A short description of the Poxvirus group (Vaccinia and related viruses). Virology 4: 305-314, 1957. PubMed: 13496547.

Craigie J. . Br. J. Exp. Pathol. 13: 259, 1932.

Parker RF, et al. Further studies of the infectious unit of Vaccinia. J. Exp. Med. 74: 263-281, 1941.

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

Basic Documentation